Institutional members access full text with Ovid®

Share this article on:

Incidence of Hepatic Dysfunction Is Equivalent in Burn Patients Receiving Oxandrolone and Controls

McCullough, Mona C. MS*; Namias, Nicholas MD, FACS, FCCM*; Schulman, Carl MD, MSPH; Gomez, Ellie PharmD; Manning, Ron RN; Goldberg, Seth PA-C.; Pizano, Louis MD, FACS; Ward, Gillon C. MD, FACS

Journal of Burn Care & Research: May-June 2007 - Volume 28 - Issue 3 - p 412-420
doi: 10.1097/BCR.0B013E318053D257
Original Articles

Oxandrolone has been shown to improve lean muscle mass in patients with burns. Hepatic dysfunction is a known side effect of treatment with oxandrolone. The purpose of this study was to examine the incidence of hepatic dysfunction in our series of burn patients receiving oxandrolone. Fourteen patients who received oxandrolone (5 mg, n = 8; 10 mg, n = 6) were identified from our prospectively collected burn database. The records of 61 control patients also were reviewed. Demographics such as age, comorbidities, and burn size were recorded. The incidence of hepatic dysfunction was determined by the presence of abnormal liver function tests. The study and control groups were similar in age and burn size. Two of the eight (25%) oxandrolone patients receiving 5 mg and four of the six (67%) oxandrolone patients receiving 10 mg had evidence of hepatic dysfunction. Twenty six of the 61 (43%) control patients had evidence of hepatic dysfunction (P = NS). There appears no significant increased incidence of hepatic dysfunction in burn patients who received oxandrolone compared to those who did not.

From the University of Miami-Miller School of Medicine, DeWitt Daughtry Family Department of Surgery, Division of Burns, Miami, Florida. *Division of Burns, Medical Director UM/JM Burn Center; and †UMMSOM Endowed Chair, Burn Surgery.

Address correspondence to Mona C. McCullough, MS, 6512 Aqueduct Court, Tallahassee, Florida 32309.

© 2007 The American Burn Association